Latest Tax Incentives News

Page 7 of 64
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026
EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.
Victor Sage
Victor Sage
26 Oct 2026
Evergold Minerals has completed a busy exploration quarter at Mt Monger, where drilling confirmed broad and high-grade gold mineralisation and identified the new Vanguard zone. The progress comes with a lower cash balance of $2.765 million and an estimated 2.28 quarters of funding at the latest spending rate.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Anatara Lifesciences narrowed its FY2026 loss and ended the year with A$470,917 in cash, but warned that further capital raising is included in its business plan and may be necessary to remain a going concern. Its AOC anti-obesity candidate produced statistically significant results in mice, while mechanism-of-action data remained inconclusive and development was placed on hold.
Victor Sage
Victor Sage
23 Oct 2026
dorsaVi has commercially launched its first wearable capable of analysing movement and delivering feedback directly on-device, while its RRAM chip program moves into fabrication and testing. The progress comes alongside a post-quarter A$3.0 million capital raising, against quarter-end cash of $1.12 million and operating cash outflow of about $996,000.
Sophie Babbage
Sophie Babbage
23 Oct 2026
Adslot reported stronger Viber advertising activity and lower operating costs in the September quarter, while restructuring payments continued to weigh on cash. The company ended the period with $1.28 million and a prescribed funding runway of 1.7 quarters.
Victor Sage
Victor Sage
23 Oct 2026
Firebrick Pharma is escalating Nasodine’s US push from online sales into retail pharmacies while its September-quarter cash balance fell to A$875,000. The company reported a A$398,000 operating cash outflow and estimated 2.2 quarters of funding at the current rate.
Victor Sage
Victor Sage
23 Oct 2026
BluGlass has expanded its customer-funded GaN laser programs with a A$1.4 million Uviquity contract and a new A$286,000 photonics collaboration. But its A$8 million facility is fully drawn, carries 16.5% interest and leaves reported funding coverage at 2.8 quarters.
Victor Sage
Victor Sage
23 Oct 2026
Amplia Therapeutics has received an A$4.78 million refundable R&D tax rebate, giving the clinical-stage biotechnology company additional cash to advance its FAK inhibitor programs. The funds will support multiple narmafotinib trials and related research, including studies involving Lilly.
Victor Sage
Victor Sage
22 Oct 2026
Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.
Ada Torres
Ada Torres
22 Oct 2026
Arovella Therapeutics has received a $4.03 million FY2026 R&D tax refund, giving the clinical-stage biotech additional cash as it advances its lead therapy ALA-101 towards first-patient dosing. The payment arrives without any accompanying clinical data or disclosed update to the company’s cash runway.
Ada Torres
Ada Torres
22 Oct 2026
Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.
Victor Sage
Victor Sage
21 Oct 2026

Browse the archive

Full archive